Replies to post #86187 on Biotech Values

[rkrw]

They could be at a big risk when/if (in pivotal studies) the bax/halo one monthly injection formulation comes out.

Talecris is working on their own injectable but it's once weekly, 4 injections and needs 40% more drug because of bioavailability issues. Given the cogs it seems like a non starter to me.